International Stem Cell Corp. is tackling some of the
world’s most debilitating health maladies with a powerful new stem cell
technology that employs parthenogenesis. Parthenogenesis is a type of
reproduction that takes place in the absence of fertilization. The company’s
new stem cell technology holds the promise of advancing significantly the field
of regenerative medicine by addressing the problem of immune-rejection. Stem
cells are able to divide in a process of self-renewal in which one cell gives
birth to two or more. They are also able to differentiate into cells of a
different type so that a stem cell originating from one part of the body may
differentiate into a type that is similar to the cells in another part of the
body.
At the top of ISCO’s list is Parkinson’s disease.
Parkinson’s is characterized by noticeable tremors of the hands. But since it
is a progressive disorder of the nervous system that affects motor functions,
it also commonly causes stiffness or slowing of movement. The Parkinson’s
Disease Foundation estimates that approximately 60,000 Americans are diagnosed
with Parkinson’s disease each year, a number that may not reflect the thousands
of cases that go undetected. About one million Americans live with the disease
and an estimated seven to ten million people worldwide are living with
Parkinson’s disease. ISCO’s UniStemCell for Parkinson’s has completed the Food
& Drug Administration (FDA)’s Investigational New Drug (IND) phase, which
means it will soon begin to undergoing clinical trials. Clinical trials occur
when the effects of new treatments on humans are studied.
ISCO’s development of neural stem cells for the treatment of
ischemic strokes is also at an advanced stage. Pre-clinical trials have been
completed, and the company is now embarking on the FDA’s IND phase. Ischemic
strokes occur as a result of an obstruction within a blood vessel supplying
blood to the brain. The Centers for Disease Control and Prevention (CDC)
estimate that, on average, one American dies from stroke every four minutes and
that more than 795,000 people in the United States have a stroke each year.
About 87% of all strokes are ischemic strokes.
ISCO is also developing treatments for spinal cord injury,
metabolic liver diseases, retinal blindness and corneal blindness. These four
treatments are all at the pre-clinical stage. Metabolic liver diseases, retinal
blindness, corneal blindness and spinal cord injuries are ailments that affect
hundreds of thousands. The National Spinal Cord Injury Statistical Center at
the University of Alabama at Birmingham estimates that between 240,000 and
337,000 people in the United States are currently living with spinal cord
injuries (SCI) and 12,500 new SCI cases occur every year.
So far ISCO has accepted no government subventions and has
been able to generate income from its two subsidiaries to help fund its
research. One subsidiary, Lifeline Skin Care, Inc., develops, produces, and
markets a line of anti-aging cosmetic skin care products. The other is Lifeline
Cell Technology, LLC, which develops, manufactures, and sells human cell
culture products along with optimized reagents for laboratory research
purposes. For the many sufferers of Parkinson’s disease and other debilitating
conditions, relief from ISCO is on the way.
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html